These findings suggest that KGA-2727 pretreatment protected against MI-induced left ventricular remodeling by blocking SGLT1, potentially offering a new therapeutic approach for ischemia-induced cardiomyopathy [157]. This evidence concerns the gene SLC5A1 and myocardial infarction.